Angiotensin II Type 1 Receptor A1166C Polymorphism and Prophylactic Indomethacin Treatment Induced Ductus Arteriosus Closure in Very Low Birth Weight Neonates

András Treszl, M. Szabó, György Dunai, András Nobilis, István Kocsis, Tamás Machay, T. Tulassay, B. Vásárhelyi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Altered pulmonary vascular resistance might be a factor for delayed closure of the ductus arteriosus (DA) in preterm infants. Angiotensin II plays a central role in the elevation of pulmonary vascular resistance. Angiotensin II exerts its vasoconstrictor effect on the angiotensin II type 1 receptor (AT1R). Homozygous carriers of the AT1R A1166C genetic variant present an exaggerated vasoconstrictor response to angiotensin II. We have investigated whether the presence of AT1R CC1166 influences the effect of prophylactic indomethacin treatment on the closure of DA until the fifth postnatal day in preterm infants. In this retrospective study detailed medical history of the first postnatal week was obtained in 159 infants born before the 33rd gestational week. All were treated by prophylactic indomethacin to induce permanent closure of the DA. On the sixth postnatal day the DA was still open in 56, whereas it was permanently closed in 103. The AT1R A 1166C genotype of the infants was determined from Guthrie spots. Stepwise binary logistic regression analysis was used to assess the effect of medical conditions and genotype on the risk of patent DA (PDA). Birth weight, infantile respiratory distress, and severe hypotension were independent risk factors for PDA (p <0.01, p <0.05, p <0.05, respectively). The carrier state of AT1R CC1166 was protective against PDA (p <0. 05; odds ratio, 0.067). AT1R AC1166 genotype was not associated with PDA. Our results indicate that the risk of PDA might be lower in infants of AT1R CC1166 than in those with AC or AA genotypes.

Original languageEnglish
Pages (from-to)753-755
Number of pages3
JournalPediatric Research
Volume54
Issue number5
DOIs
Publication statusPublished - Nov 2003

Fingerprint

Ductus Arteriosus
Angiotensin Type 1 Receptor
Very Low Birth Weight Infant
Indomethacin
Newborn Infant
Patents
Genotype
Angiotensin II
Vasoconstrictor Agents
Premature Infants
Vascular Resistance
Therapeutics
Carrier State
Patent Ductus Arteriosus
Birth Weight
Hypotension
Retrospective Studies
Logistic Models
Odds Ratio
Regression Analysis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Angiotensin II Type 1 Receptor A1166C Polymorphism and Prophylactic Indomethacin Treatment Induced Ductus Arteriosus Closure in Very Low Birth Weight Neonates. / Treszl, András; Szabó, M.; Dunai, György; Nobilis, András; Kocsis, István; Machay, Tamás; Tulassay, T.; Vásárhelyi, B.

In: Pediatric Research, Vol. 54, No. 5, 11.2003, p. 753-755.

Research output: Contribution to journalArticle

@article{1d2485dcb0ef461ca35dc0e51f0ab9eb,
title = "Angiotensin II Type 1 Receptor A1166C Polymorphism and Prophylactic Indomethacin Treatment Induced Ductus Arteriosus Closure in Very Low Birth Weight Neonates",
abstract = "Altered pulmonary vascular resistance might be a factor for delayed closure of the ductus arteriosus (DA) in preterm infants. Angiotensin II plays a central role in the elevation of pulmonary vascular resistance. Angiotensin II exerts its vasoconstrictor effect on the angiotensin II type 1 receptor (AT1R). Homozygous carriers of the AT1R A1166C genetic variant present an exaggerated vasoconstrictor response to angiotensin II. We have investigated whether the presence of AT1R CC1166 influences the effect of prophylactic indomethacin treatment on the closure of DA until the fifth postnatal day in preterm infants. In this retrospective study detailed medical history of the first postnatal week was obtained in 159 infants born before the 33rd gestational week. All were treated by prophylactic indomethacin to induce permanent closure of the DA. On the sixth postnatal day the DA was still open in 56, whereas it was permanently closed in 103. The AT1R A 1166C genotype of the infants was determined from Guthrie spots. Stepwise binary logistic regression analysis was used to assess the effect of medical conditions and genotype on the risk of patent DA (PDA). Birth weight, infantile respiratory distress, and severe hypotension were independent risk factors for PDA (p <0.01, p <0.05, p <0.05, respectively). The carrier state of AT1R CC1166 was protective against PDA (p <0. 05; odds ratio, 0.067). AT1R AC1166 genotype was not associated with PDA. Our results indicate that the risk of PDA might be lower in infants of AT1R CC1166 than in those with AC or AA genotypes.",
author = "Andr{\'a}s Treszl and M. Szab{\'o} and Gy{\"o}rgy Dunai and Andr{\'a}s Nobilis and Istv{\'a}n Kocsis and Tam{\'a}s Machay and T. Tulassay and B. V{\'a}s{\'a}rhelyi",
year = "2003",
month = "11",
doi = "10.1203/01.PDR.0000088016.67117.39",
language = "English",
volume = "54",
pages = "753--755",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Angiotensin II Type 1 Receptor A1166C Polymorphism and Prophylactic Indomethacin Treatment Induced Ductus Arteriosus Closure in Very Low Birth Weight Neonates

AU - Treszl, András

AU - Szabó, M.

AU - Dunai, György

AU - Nobilis, András

AU - Kocsis, István

AU - Machay, Tamás

AU - Tulassay, T.

AU - Vásárhelyi, B.

PY - 2003/11

Y1 - 2003/11

N2 - Altered pulmonary vascular resistance might be a factor for delayed closure of the ductus arteriosus (DA) in preterm infants. Angiotensin II plays a central role in the elevation of pulmonary vascular resistance. Angiotensin II exerts its vasoconstrictor effect on the angiotensin II type 1 receptor (AT1R). Homozygous carriers of the AT1R A1166C genetic variant present an exaggerated vasoconstrictor response to angiotensin II. We have investigated whether the presence of AT1R CC1166 influences the effect of prophylactic indomethacin treatment on the closure of DA until the fifth postnatal day in preterm infants. In this retrospective study detailed medical history of the first postnatal week was obtained in 159 infants born before the 33rd gestational week. All were treated by prophylactic indomethacin to induce permanent closure of the DA. On the sixth postnatal day the DA was still open in 56, whereas it was permanently closed in 103. The AT1R A 1166C genotype of the infants was determined from Guthrie spots. Stepwise binary logistic regression analysis was used to assess the effect of medical conditions and genotype on the risk of patent DA (PDA). Birth weight, infantile respiratory distress, and severe hypotension were independent risk factors for PDA (p <0.01, p <0.05, p <0.05, respectively). The carrier state of AT1R CC1166 was protective against PDA (p <0. 05; odds ratio, 0.067). AT1R AC1166 genotype was not associated with PDA. Our results indicate that the risk of PDA might be lower in infants of AT1R CC1166 than in those with AC or AA genotypes.

AB - Altered pulmonary vascular resistance might be a factor for delayed closure of the ductus arteriosus (DA) in preterm infants. Angiotensin II plays a central role in the elevation of pulmonary vascular resistance. Angiotensin II exerts its vasoconstrictor effect on the angiotensin II type 1 receptor (AT1R). Homozygous carriers of the AT1R A1166C genetic variant present an exaggerated vasoconstrictor response to angiotensin II. We have investigated whether the presence of AT1R CC1166 influences the effect of prophylactic indomethacin treatment on the closure of DA until the fifth postnatal day in preterm infants. In this retrospective study detailed medical history of the first postnatal week was obtained in 159 infants born before the 33rd gestational week. All were treated by prophylactic indomethacin to induce permanent closure of the DA. On the sixth postnatal day the DA was still open in 56, whereas it was permanently closed in 103. The AT1R A 1166C genotype of the infants was determined from Guthrie spots. Stepwise binary logistic regression analysis was used to assess the effect of medical conditions and genotype on the risk of patent DA (PDA). Birth weight, infantile respiratory distress, and severe hypotension were independent risk factors for PDA (p <0.01, p <0.05, p <0.05, respectively). The carrier state of AT1R CC1166 was protective against PDA (p <0. 05; odds ratio, 0.067). AT1R AC1166 genotype was not associated with PDA. Our results indicate that the risk of PDA might be lower in infants of AT1R CC1166 than in those with AC or AA genotypes.

UR - http://www.scopus.com/inward/record.url?scp=0142148058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142148058&partnerID=8YFLogxK

U2 - 10.1203/01.PDR.0000088016.67117.39

DO - 10.1203/01.PDR.0000088016.67117.39

M3 - Article

C2 - 12904590

AN - SCOPUS:0142148058

VL - 54

SP - 753

EP - 755

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 5

ER -